Episodes (Page 6)
✨
Carna Health is working to combat the global chronic kidney disease crisis.
Salvatore Viscomi
✨
Xu Hu discussed China's first siRNA firm going public.
✨
Life Sciences Hub Wales supports oncology and cardiovascular technologies.
✨
Ellie Adams shared insights on cracking China's consumer health market.
Ellie Adams
✨
Adrian Woolfson discussed Artificial Biological Intelligence and genome writing.
Adrian Woolfson
✨
Iran port blockade impacts global pharma; Bayer remains committed to Europe.
✨
Iran blockade's impact on global pharma; Bayer stays in Europe.
✨
Focus on Akeso's enavatuzumab potentially changing first-line lung cancer treatment.
✨
Biotech models are evolving, requiring new approaches to value creation.
Claire Riches
Ross Pettit
✨
Attorneys discussed recent trends in biopharmaceutical M&A activity.
Bill Roegge
Kevin Cooper
✨
Icotyde could be J&J's biggest product.
✨
J&J's Icotyde potential; Revolution's daraxonrasib data.
✨
Adrian van den Hoven discusses environmental regulations.
✨
Houman David Hemmati is floated as the next CBER director candidate.
Houman David Hemmati
Sara Brenner
✨
Samsung Bioepis is strengthening its differentiation strategy in the ADC market.
✨
Key commercial and regulatory developments in Japan's biopharma market for Q1.
Ian Haydock
Lisa Takagi
✨
Lilly TuneLab uses federated learning to let biotechs access AI models without sharing data.
Federated Learning
✨
Trump's 100% tariffs on some drugs and APIs create uncertainty.
✨
Trump's 100% tariffs on some drugs and APIs create uncertainty.
✨
FDA updates leucovorin labeling, leading GSK to re-withdraw its application.
Bridget Silverman
Nielsen Hobbs